Heart Rate Variability as a Potential Predictor of Response to Intranasal Esketamine in Patients with Treatment-Resistant Depression: A Preliminary Report.
Journal of Clinical Medicine August 14, 2024 Lorenzo Moccia, Giovanni Bartolucci, Maria Pepe et al. 7 citations
Background: Esketamine has received approval as a nasal spray (ESK-NS) for treatment-resistant depression (TRD) and evidence from real-world investigations has confirmed the effectiveness of ESK-NS, albeit with interindividual differences in response. Heart rate variability (HRV), defined as the fluctuation in time interval between consecutive heartbeats, can be used to measure autonomic...
DOI: 10.3390/jcm13164767 (opens in new tab)
Full text (opens in new tab)
Esketamine
Mood disorders
Personalized medicine
Mental-health
+4